Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice

Komal Sodhi, Kazuyoshi Inoue, Katherine H. Gotlinger, Martina Canestraro, Luca Vanella, Dong Hyun Kim, Vijay L. Manthati, Sreenivasulu Reddy Koduru, J R Falck, Michal L. Schwartzman, Nader G. Abraham

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Heme oxygenase (HO) and cytochrome P450 (P450)-derived epoxyeicosatrienoic acids (EETs) participate in vascular protection, and recent studies suggest these two systems are functionally linked. We examined the consequences of HO deficiency on P450-derived EETs with regard to body weight, adiposity, insulin resistance, blood pressure, and vascular function in HO-2-null mice. The HO-2-null mice were obese, displayed insulin resistance, and had high blood pressure. HO-2 deficiency was associated with decreases in cyp2c expression, EET levels, HO-1 expression, and HO activity and with an increase in superoxide production and an impairment in the relaxing response to acetylcholine. In addition, HO-2-null mice exhibited increases in serum levels of tumor necrosis factor (TNF)-α and macrophage chemoattractant protein (MCP)-1 and a decrease in serum adiponectin levels. Treatment of HO-2-null mice with a dual-activity EET agonist/soluble epoxide hydrolase inhibitor increased renal and vascular EET levels and HO-1 expression, lowered blood pressure, prevented body weight gain, increased insulin sensitivity, reduced subcutaneous and visceral fat, and decreased serum TNF-α and MCP-1, while increasing adiponectin and restoring the relaxing responses to acetylcholine. The decrease in cyp2c expression and EETs levels in HO-2-null mice underscores the importance of the HO system in the regulation of epoxygenase levels and suggests that protection against obesity-induced cardiovascular complications requires interplay between these two systems. A deficiency in one of these protective systems may contribute to the adverse manifestations associated with the clinical progression of the metabolic syndrome.

Original languageEnglish (US)
Pages (from-to)906-916
Number of pages11
JournalJournal of Pharmacology and Experimental Therapeutics
Volume331
Issue number3
DOIs
StatePublished - Dec 2009

Fingerprint

Heme Oxygenase (Decyclizing)
Phenotype
Acids
Blood Vessels
Insulin Resistance
Heme Oxygenase-1
Adiponectin
Chemotactic Factors
Acetylcholine
Tumor Necrosis Factor-alpha
Serum
Macrophages
Body Weight
Blood Pressure
Epoxide Hydrolases
Obese Mice
Intra-Abdominal Fat
Subcutaneous Fat
Adiposity
Superoxides

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Medicine(all)

Cite this

Sodhi, K., Inoue, K., Gotlinger, K. H., Canestraro, M., Vanella, L., Kim, D. H., ... Abraham, N. G. (2009). Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. Journal of Pharmacology and Experimental Therapeutics, 331(3), 906-916. https://doi.org/10.1124/jpet.109.157545

Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. / Sodhi, Komal; Inoue, Kazuyoshi; Gotlinger, Katherine H.; Canestraro, Martina; Vanella, Luca; Kim, Dong Hyun; Manthati, Vijay L.; Koduru, Sreenivasulu Reddy; Falck, J R; Schwartzman, Michal L.; Abraham, Nader G.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 331, No. 3, 12.2009, p. 906-916.

Research output: Contribution to journalArticle

Sodhi, K, Inoue, K, Gotlinger, KH, Canestraro, M, Vanella, L, Kim, DH, Manthati, VL, Koduru, SR, Falck, JR, Schwartzman, ML & Abraham, NG 2009, 'Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice', Journal of Pharmacology and Experimental Therapeutics, vol. 331, no. 3, pp. 906-916. https://doi.org/10.1124/jpet.109.157545
Sodhi, Komal ; Inoue, Kazuyoshi ; Gotlinger, Katherine H. ; Canestraro, Martina ; Vanella, Luca ; Kim, Dong Hyun ; Manthati, Vijay L. ; Koduru, Sreenivasulu Reddy ; Falck, J R ; Schwartzman, Michal L. ; Abraham, Nader G. / Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. In: Journal of Pharmacology and Experimental Therapeutics. 2009 ; Vol. 331, No. 3. pp. 906-916.
@article{5b8530d798cf41259fad4983b381ca98,
title = "Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice",
abstract = "Heme oxygenase (HO) and cytochrome P450 (P450)-derived epoxyeicosatrienoic acids (EETs) participate in vascular protection, and recent studies suggest these two systems are functionally linked. We examined the consequences of HO deficiency on P450-derived EETs with regard to body weight, adiposity, insulin resistance, blood pressure, and vascular function in HO-2-null mice. The HO-2-null mice were obese, displayed insulin resistance, and had high blood pressure. HO-2 deficiency was associated with decreases in cyp2c expression, EET levels, HO-1 expression, and HO activity and with an increase in superoxide production and an impairment in the relaxing response to acetylcholine. In addition, HO-2-null mice exhibited increases in serum levels of tumor necrosis factor (TNF)-α and macrophage chemoattractant protein (MCP)-1 and a decrease in serum adiponectin levels. Treatment of HO-2-null mice with a dual-activity EET agonist/soluble epoxide hydrolase inhibitor increased renal and vascular EET levels and HO-1 expression, lowered blood pressure, prevented body weight gain, increased insulin sensitivity, reduced subcutaneous and visceral fat, and decreased serum TNF-α and MCP-1, while increasing adiponectin and restoring the relaxing responses to acetylcholine. The decrease in cyp2c expression and EETs levels in HO-2-null mice underscores the importance of the HO system in the regulation of epoxygenase levels and suggests that protection against obesity-induced cardiovascular complications requires interplay between these two systems. A deficiency in one of these protective systems may contribute to the adverse manifestations associated with the clinical progression of the metabolic syndrome.",
author = "Komal Sodhi and Kazuyoshi Inoue and Gotlinger, {Katherine H.} and Martina Canestraro and Luca Vanella and Kim, {Dong Hyun} and Manthati, {Vijay L.} and Koduru, {Sreenivasulu Reddy} and Falck, {J R} and Schwartzman, {Michal L.} and Abraham, {Nader G.}",
year = "2009",
month = "12",
doi = "10.1124/jpet.109.157545",
language = "English (US)",
volume = "331",
pages = "906--916",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice

AU - Sodhi, Komal

AU - Inoue, Kazuyoshi

AU - Gotlinger, Katherine H.

AU - Canestraro, Martina

AU - Vanella, Luca

AU - Kim, Dong Hyun

AU - Manthati, Vijay L.

AU - Koduru, Sreenivasulu Reddy

AU - Falck, J R

AU - Schwartzman, Michal L.

AU - Abraham, Nader G.

PY - 2009/12

Y1 - 2009/12

N2 - Heme oxygenase (HO) and cytochrome P450 (P450)-derived epoxyeicosatrienoic acids (EETs) participate in vascular protection, and recent studies suggest these two systems are functionally linked. We examined the consequences of HO deficiency on P450-derived EETs with regard to body weight, adiposity, insulin resistance, blood pressure, and vascular function in HO-2-null mice. The HO-2-null mice were obese, displayed insulin resistance, and had high blood pressure. HO-2 deficiency was associated with decreases in cyp2c expression, EET levels, HO-1 expression, and HO activity and with an increase in superoxide production and an impairment in the relaxing response to acetylcholine. In addition, HO-2-null mice exhibited increases in serum levels of tumor necrosis factor (TNF)-α and macrophage chemoattractant protein (MCP)-1 and a decrease in serum adiponectin levels. Treatment of HO-2-null mice with a dual-activity EET agonist/soluble epoxide hydrolase inhibitor increased renal and vascular EET levels and HO-1 expression, lowered blood pressure, prevented body weight gain, increased insulin sensitivity, reduced subcutaneous and visceral fat, and decreased serum TNF-α and MCP-1, while increasing adiponectin and restoring the relaxing responses to acetylcholine. The decrease in cyp2c expression and EETs levels in HO-2-null mice underscores the importance of the HO system in the regulation of epoxygenase levels and suggests that protection against obesity-induced cardiovascular complications requires interplay between these two systems. A deficiency in one of these protective systems may contribute to the adverse manifestations associated with the clinical progression of the metabolic syndrome.

AB - Heme oxygenase (HO) and cytochrome P450 (P450)-derived epoxyeicosatrienoic acids (EETs) participate in vascular protection, and recent studies suggest these two systems are functionally linked. We examined the consequences of HO deficiency on P450-derived EETs with regard to body weight, adiposity, insulin resistance, blood pressure, and vascular function in HO-2-null mice. The HO-2-null mice were obese, displayed insulin resistance, and had high blood pressure. HO-2 deficiency was associated with decreases in cyp2c expression, EET levels, HO-1 expression, and HO activity and with an increase in superoxide production and an impairment in the relaxing response to acetylcholine. In addition, HO-2-null mice exhibited increases in serum levels of tumor necrosis factor (TNF)-α and macrophage chemoattractant protein (MCP)-1 and a decrease in serum adiponectin levels. Treatment of HO-2-null mice with a dual-activity EET agonist/soluble epoxide hydrolase inhibitor increased renal and vascular EET levels and HO-1 expression, lowered blood pressure, prevented body weight gain, increased insulin sensitivity, reduced subcutaneous and visceral fat, and decreased serum TNF-α and MCP-1, while increasing adiponectin and restoring the relaxing responses to acetylcholine. The decrease in cyp2c expression and EETs levels in HO-2-null mice underscores the importance of the HO system in the regulation of epoxygenase levels and suggests that protection against obesity-induced cardiovascular complications requires interplay between these two systems. A deficiency in one of these protective systems may contribute to the adverse manifestations associated with the clinical progression of the metabolic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=73349106519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349106519&partnerID=8YFLogxK

U2 - 10.1124/jpet.109.157545

DO - 10.1124/jpet.109.157545

M3 - Article

VL - 331

SP - 906

EP - 916

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -